Objectives: To explore the following aspects of teicoplanin use in patients with haematological 22 malignancy: early attainment of target trough concentrations with current high dose teicoplanin 23 regimens; variability in unbound teicoplanin fractions; factors associated with observed total and 24 unbound trough concentrations; efficacy and toxicity; and renal function estimation. 25
Introduction 44
Infection is one of the most common complications of chemotherapy-induced neutropaenia (1). 45
Haematological malignancy patients have the greatest risk for severe neutropaenia, compared to 46 solid tumour patients, because of the underlying disease as well as the severely myelosuppressive 47 chemotherapy used for treatment (2). The increasing incidence of Gram-positive pathogens in these 48 patients is well recognised and, as these pathogens are often meticillin-resistant, glycopeptide 49 antibiotics, commonly teicoplanin or vancomycin, have an important role in their treatment (1). 50
Teicoplanin is considered to be a useful alternative to vancomycin -it is equally effective, can be 51 administered once daily and is associated with fewer side-effects (3). Indeed, surveys conducted in 52 the UK and Ireland have found teicoplanin to commonly be the preferred choice for patients with 53 haematological malignancy (4, 5). However, the emergence of teicoplanin-resistance is a significant 54 concern (6-8) and, coupled with the impaired ability of neutropaenic patients to fight infection, 55 makes it important to achieve adequate exposure rapidly (9) . 56
The ratio of the area under the concentration-time curve to the minimum inhibitory concentration 57 (AUC/MIC) is thought to be the pharmacokinetic/pharmacodynamic index best correlating with 58 glycopeptide efficacy (10-12). However, calculating AUC requires multiple samples and therefore 59 trough concentrations are used as a surrogate marker to assess exposure in daily clinical practice 60 (13). Whilst the Summary of Product Characteristics specifies a target trough concentration of 61 ≥10 mg/L for most infections (14), a higher trough target has been advocated for haematological 62 malignancy patients (15, 16) . Indeed, the trough target recommended at Tallaght Hospital for 63 teicoplanin in haematological malignancy patients is ≥20 mg/L, with higher than conventional doses 64 specified to achieve this. 65
As teicoplanin is highly protein bound (90-95%) (17), altered serum albumin concentrations may 66 have variable effects on total and unbound concentrations (18). Knowledge of unbound 67 concentrations may be more relevant than total concentrations to predict outcome as unbound 68 concentrations are responsible for antimicrobial activity and correlate best with drug response (18) . 69
Previous data have suggested that albumin concentrations play a major role in the variability of the 70 unbound (free) fraction (FF) of teicoplanin (13, (19) (20) (21) . Altered FFs of teicoplanin and a lack of 71 correlation between unbound and total concentrations might also be expected in haematological 72 malignancy patients where low albumin concentrations are common (22) . 73 We previously reported a mixed effects regression model explaining 52% of the variability in 74 teicoplanin trough total concentrations in haematological malignancy patients and identified dose, 75 day of therapy, renal function and a diagnosis of acute myeloid leukaemia (AML) as significant 76 factors associated with trough total concentrations (16). However, due to the retrospective nature 77 of that study, critical characteristics that might also affect trough concentrations were not available, 78 including fluid balance, illness severity measures and measured creatinine clearance (CL CR ). 79
Furthermore, there was a lack of consistency in both dosing and day of trough concentration 80
measurements. 81
The objectives of this study were: (i) to assess whether current high dosing regimens of teicoplanin 82 result in attainment of the target trough concentration on Days 3 and 4; (ii) to determine the 83 variability in FFs of teicoplanin; (iii) to identify factors associated with both total and unbound trough 84 concentrations attained on Days 3 and 4; (iv) to describe efficacy and toxicity; and (v) 
Study population 97
The inclusion criteria were: (i) diagnosed with a haematological malignancy; (ii) age ≥18 years; (iii) 98 treated with teicoplanin for >48 h; (iv) intravascular catheter present; and (v) written informed 99 consent obtained. The exclusion criteria were: (i) receiving renal replacement therapy; (ii) admitted 100 to the Intensive Care Unit; (iii) incapable of comprehending the nature and scope of the trial; and (iv) 101 blood sampling personnel/analyst/processing equipment not available. 102
Dosing regimen 103
Teicoplanin (Targocid®, Sanofi, Dublin, Ireland) was administered intravenously by slow bolus injection. 104
The hospital dosage regimen was 600 mg (or 800 mg if weight >80 kg) 12-h for three loading doses 105 followed by 600 mg (or 800 mg if weight >80 kg) once daily. However, prescribed dosing regimens were 106 at the discretion of treating physicians and the hospital dosage regimen was not always followed. 107
Blood sampling, handling, storage and measurement 108
Trough samples (24 h post-dose) were taken on Days 3 (48 h), 4 (72 h), and 7 and 10 (when 109 applicable). Samples were immediately refrigerated and centrifuged within 6 h at 3000 rpm for 110 10 min. The supernatant was stored at -80°C until analysis. Total and unbound teicoplanin 111 concentrations were determined using HPLC as described by Roberts et al (13) . 112
Determination of CL CR 113
Urine was collected over a 24 h period on Day 3. The volume of urine was measured and a 1 mL aliquot 114 stored at -80°C until analysis. Urine creatinine concentration was determined locally using an enzymatic 115 method performed on a Roche/Hitachi Cobas C702 AutoAnalyzer system (Roche Diagnostics GmbH, 116
Mannheim, Germany). Urine volume, serum creatinine concentration (Scr) on the day of the urine 117 collection and urine creatinine concentration were used to calculate the measured CL CR . 118
MIC testing 119
The identification of isolates from study patients was determined locally by broth microdilution using a 120 VITEK®2 system (bioMérieux UK Ltd., Basingstoke, UK) as per routine care. Teicoplanin MICs of positive isolates from blood cultures taken from study patients were determined locally with MIC test 122 strips (Liofilchem, Italy) . 123
Additional data 124
Additional clinical and demographic data including age, body weight, height, serum albumin 125 concentration, blood counts, 24 h fluid balance on Day 3, and measures of illness severity including the 126
Multinational Association for Supportive Care in Cancer (MASCC) risk-index score (23), and the Charlson 127 co-morbidity index (24), were collected. If a laboratory value was missing on a particular day, the next 128 closest value to that day was used, provided it was within 2 days of the missing value. 129
Ideal body weight (IBW) was estimated using the Devine equation (25) 
Factors associated with trough concentrations attained 136
The relationship between patient factors and trough total concentrations at 48 h (trough 48h-total ) and 137 72 h (trough 72h-total ), and trough unbound concentrations at 48 h (trough 48h-unbound ) and 72 h 138 (trough 72h-unbound ) attained, were assessed. Log trough concentrations were used for the dependent 139 variable as the data were positively skewed. Independent variables tested included: age; haematological 140 malignancy diagnosis; receipt of a bone marrow transplant; sickness severity scores; measured CL CR 141 (Day 3 only), eCL CR and eGFR; serum albumin concentration; fluid balance and fluid input. 142
Step-wise incorporation of covariates was conducted for multivariate model development with 143 cumulative dose (mg/kg) included in all models. Covariates that did not contribute to, or reduced the fit 144 of, the model were removed sequentially and only significant covariates were retained. The target total7 trough concentration was 20 mg/L, and the target unbound trough concentration was 1.5 mg/L, 146 assuming 92.5% protein binding. These targets were based on those suggested from previously 147 published studies (13, 15, 16) . 148
Comparison of renal function estimation equations 149
The performances of renal function estimation equations for estimating measured CL CR were 150 compared. The CG-TBW, CG-IBW and MDRDa estimates were compared with measured CL CR in 151 mL/min. The MDRD, CKD-EPI and JEL estimates were compared with measured CL CR in 152 mL/min/1.73 m 2 . Bias was assessed as the median difference, with positive values indicating over-153 estimation of measured CL CR . Precision was assessed as IQR for the differences. Accuracy was 154 assessed as root mean square error and percent of estimates within 30% of measured CL CR (30) . 155
Response to teicoplanin therapy 156
Assessment of response to teicoplanin therapy was conducted using the same methods and definitions 157 as previously described by Byrne et al (16) . 158
Nephrotoxicity and hepatotoxicity 159
Nephrotoxicity was assessed by comparing Scr on the first and last days of teicoplanin therapy. 160
Nephrotoxicity was defined as an increase in Scr of >0.5 mg/dL or ≥50% (31). 161
Hepatotoxicity was assessed by comparing serum alanine transaminase (ALT) on the first and last days 162 of teicoplanin therapy and was defined as an increase in ALT of >3 times the upper limit of normal or >3 163 times baseline if the level was abnormal on Day 1 (31). 164
Statistical analyses 165
All statistical analyses were conducted using IBM SPSS Statistics for Windows v. 22 (IBM Corp., Armonk, 166 NY) or Minitab 16 Statistical Software (Minitab Ltd., Coventry, UK). Data were described as the mean ± 167 SD or the median (IQR) for continuous variables, and as the number (%) for categorical variables. Either 168 unpaired Student's t-test or non-parametric Mann-Whitney U-test was used to compare groups for 169 continuous variables. Fisher's exact test was used to compare groups for categorical covariates.
Simple and multiple regression analyses were used to assess the relationship between patient factors 172 and trough concentrations. Statistical significance was defined as P<0.05. 173
174

Results
175
Thirty patients were recruited into the study. A summary of demographic and clinical characteristics 176 of included patients are provided in Table 1 . Coagulase-negative staphylococcal (CoNS) central line-177 associated blood stream infection (CLABSI) was the most common microbiologically documented 178 infection occurring in the cohort (n=7, 33.3%). Three patients (10%) died during their admission and 179 this was attributed to progression of the malignancy in all cases. 180
Dosing regimens 181
All 30 patients received three initial loading doses ranging from 330 mg to 800 mg (4.7-13.8 mg/kg). 182
Twenty nine patients received once daily maintenance doses of 600 mg or 800 mg 183 (7.3-13.8 mg/kg/day). One patient received 800 mg once daily (8.8 mg/kg) up to Day 8 and then 184 twice daily thereafter. The duration of teicoplanin therapy ranged from 3-20 days. 185
Trough concentrations 186
High interpatient variability in trough total and unbound concentrations was observed. Fig. 1  187 summarises observed total and unbound trough concentrations on Days 3, 4, 7 and 10, and 188 illustrates the accumulation of total and unbound teicoplanin over time. 189
The proportions of patients with a trough 48h-total and trough 72h-total of ≥20 mg/L were 16.7% (5/30) 190 and 37.9% (11/29), respectively. The proportions of patients with a trough 48h-unbound and trough 72h-191 unbound of ≥1.5 mg/L were 26.7% (8/30) and 37.9% (11/29), respectively. There was a moderate 192 correlation between total and unbound trough concentrations at 48 h and at 72 h (r=0. 721, P<0.001; 193 and r=0.692, P<0.001, respectively) (Fig. 2) . The FFs of teicoplanin showed high interpatient 194 variation, with FFs ranging from 3.4-18.8%. Higher FFs were observed in patients with low serum 195 albumin concentrations (Fig. 3) . 196
Factors associated with trough concentrations attained9 All 30 patients were included in analyses of 48 h trough concentrations. Twenty nine patients were 198 included in analyses of 72 h trough concentrations, with one patient excluded due to lack of trough 199 measurement at this time. A CL CR of 1 mL/min was assumed for one patient based on the urine 200 output of ~10 mL on this day. 201
Trough 48h-total 202
The only factors significantly associated with the log trough 48h-total were eGFR using the MDRD 203 According to this model, for a standard 70 kg patient with a CL CR of 70 mL/min, the estimated 233 loading regimen to achieve a trough 72h-unbound of 1.5 mg/L is 900 mg (13 mg/kg) 12-h for three doses 234 and then a further dose 24 h later. 235
Comparison of renal function estimation equations 236 
Response to teicoplanin therapy 246
Of the 30 febrile episodes, seven cases were deemed evaluable for assessment of response to 247 teicoplanin and all were meticillin-resistant CoNS CLABSIs. Of these, there were four successful 248 outcomes and three failures. The median time to failure was 8 days (range 3-14 days). Causes offailure were persistence of fever in two cases and persistence of both fever and pathogen in one 250 case. Central lines were retained in all successful cases but not in the three failures. 251
There was no significant difference in clinical or demographic factors between successful and failed 252 cases. The mean ± SD trough total and unbound concentrations, and trough total/MIC and trough 253 unbound/MIC ratios, were higher in successful than in failed cases, although the differences were 254 not statistically significant (Table 3) . 255
Adverse events 256
Overall, teicoplanin was well tolerated. Four patients developed skin rash (13.3%), but in all cases 257 other medications with known potential to cause skin rash were used concurrently. A severe 258 hypersensitivity reaction developed in one patient, within minutes after the IV infusion commenced, 259 despite being treated with teicoplanin on a previous admission without consequence. 260 Nephrotoxicity was observed in five patients (16.7%). Of these, four were co-treated with other 261 potentially nephrotoxic drugs and most often this was an aminoglycoside. In the remaining case, the 262 onset of acute kidney injury ensued 3 days before teicoplanin was commenced. The findings of this prospective study provide further evidence that higher loading doses of 273 teicoplanin are needed in patients with haematological malignancy. For an average haematological 274 malignancy patient, the regression models developed suggest that sequential loading doses of atleast 12 mg/kg would be needed to achieve early adequate exposure. Loading doses of 12 mg/kg 276 12-h for 3-5 doses are currently recommended for bone and joint infections to achieve trough 277 concentrations of ≥20 mg/L (14). Adopting these dosing recommendations for haematological 278 malignancy patients may be an appropriate consideration. 279
Consistent with studies in other patient groups (13, (19) (20) (21) , FFs of teicoplanin were highly variable in 280 study patients, with higher FFs observed in patients with low serum albumin concentrations. In 281 recent years, the importance of therapeutic drug monitoring (TDM) of unbound teicoplanin 282 concentrations has been highlighted for critically ill and chronically ill patients (13, 20, 21) . Given the 283 observed variability in protein binding and the lack of a strong correlation between trough total and 284 unbound concentrations, TDM of unbound teicoplanin concentrations may prove useful in the 285
future. 286
The regression analyses showed that renal function is an important consideration for appropriate 287 initial teicoplanin dosing, which is in keeping with the findings of recently published studies (16, 32, 288 33) . Although the impact of renal function on trough concentrations was stronger at 72 h compared 289 to at 48 h, the results suggest that in patients with enhanced renal function, achieving target trough 290 concentrations may be difficult unless very high loading doses, such as >20 mg/kg, are used. 291
Measured CL CR had a stronger association with trough concentrations than estimated values 292 calculated using renal function estimation equations. Should measured CL CR data not be available, 293
given the experience of use in clinical practice and the results of the comparison of renal function 294 estimation equations, eCL CR calculated using the CG-TBW equation could be proposed as a surrogate 295 for measured CL CR in this patient group. 296
In our previous retrospective study, a diagnosis of AML showed a significant negative association 297 with trough total concentrations (16), although this was not found to be the case in the current 298 study. This may have been due to the smaller sample size and lower number of AML patients in the 299 current study (n=7) compared to the retrospective study (n=20). We postulated that AML patients 300 may have different underlying pathophysiology compared to patients with other types ofhaematological malignancy, including higher fluid loads, inflammation and/or severity of illness. 302 Indeed in the current study, fluid input and MASCC score were significantly associated with trough 303 concentrations. The MASCC score is a composite score, used to identify the risk of complications in 304 febrile neutropaenic cancer patients, with lower scores indicating a higher risk of complications (23). 305
It is possible that lower MASCC scores reflect altered pathophysiology and/or the use of supportive 306 treatments, such as aggressive fluid therapy, in sicker patients, resulting in enhanced disposition of 307 teicoplanin. 308
Demonstrating a relationship between teicoplanin concentrations and clinical outcome would have 309 been useful to guide practice in this patient group. However, establishing the efficacy of an 310
individual antibacterial agent is difficult in neutropaenic patients because antibacterial treatment is 311 often prescribed empirically and these patients are frequently on several antibacterial agents 312 concurrently. Such was the case in the current study, with only seven patients being evaluable for 313 assessment of teicoplanin efficacy and therefore no further insight into the appropriate trough 314 target for teicoplanin in haematological malignancy patients was gained. Nevertheless, the 315 mean ± SD trough 48h-total of 18.6 ± 12.3 mg/L and trough 72h-total of 22.8 ± 15.2 mg/L, observed in 316 successful cases in the current study, were consistent with previous studies suggesting a target 317 trough of 20 mg/L (15, 16). 318
Of course, the benefits of using higher teicoplanin doses to produce higher trough concentrations 319 must be balanced against the potential risk of increased toxicity. In the current study, with trough 320 concentrations ranging from 4.1-70.5 mg/L between Days 3 and 10, teicoplanin was well tolerated. 321
Apart from the severe hypersensitivity reaction in one patient, none of the adverse events observed 322 could definitely be attributed to teicoplanin. Furthermore, no relationship between trough 323 concentrations and incidence of adverse events was observed. 324
This study had several limitations. Firstly, the study was conducted in a single centre and the sample 325 size was small. Secondly, no conclusions could be made about the relationship between drug 326 positive infections. Thirdly, the current study does not allow statements to be made about the 328 relationship between trough levels and toxicity outside the range observed in this study. Fourthly, 329 therapeutic targets for teicoplanin are not well defined and therefore the dosing estimations may be 330 different should new targets be determined in the future. 331
In conclusion, to achieve target trough concentrations early in therapy, higher loading doses of 332 teicoplanin than those in current use appear necessary in patients with haematological malignancy. 333
Renal function is an important consideration for appropriate initial dosing of teicoplanin. Serum 334 albumin concentration has a significant effect on unbound teicoplanin concentrations. 
